ischemic cardiomyopathy

^[1]^[2]^[3]^[4]

Etiology

also see ischemic heart disease & dilated cardiomyopathy
CABG significantly outperforms medical therapy for all-cause mortality (59 vs 66% over 9.8 years)^[2]
myocardial viability does not predict benefit from revascularization or mortality^[3]
no benefit to percutaneous coronary intervention^[4]
stem cell therapy is investigational
- older age does not diminish improvements after stem cell therapy^[1]

↑ ^1.0 ^1.1 Golpanian S et al. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J Am Coll Cardiol 2015 Jan 20; 65:125 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25593053 <Internet> http://www.sciencedirect.com/science/article/pii/S0735109714069496
↑ ^2.0 ^2.1 Velazquez EJ et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016 Apr 3; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27040723 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1602001
Guyton RA, Smith AL. Coronary bypass - Survival benefit in heart failure. N Engl J Med 2016 Apr 3 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27040599 <Internet> http://www.nejm.org/doi/10.1056/NEJMe1603615
↑ ^3.0 ^3.1 Panza JA, Ellis AM, Al-Khalidi HR et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med 2019 Aug 22; 381:739 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31433921 https://www.nejm.org/doi/10.1056/NEJMoa1807365
↑ ^4.0 ^4.1 Perera D et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 2022 Aug 27; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36027563 https://www.nejm.org/doi/10.1056/NEJMoa2206606